Clinical Trials

Chevy Chase Clinical Research is the largest research program of its kind in the region. Established in 1996 as part of Affiliated Research Centers, it is now an independent research site within Capital Digestive Care. More than 300 studies have been conducted in all areas of gastroenterology and some areas of internal medicine. Active clinical trials are summarized below. If you think you may be a candidate for enrollment in one of our active clinical trials, please contact us at:
erin.klepeis@capitaldigestivecare.com / (301) 652-5520

C. Diff

This study is for patients who currently test positive for Clostridium difficile, better known as C. Diff. The study medication will be an intravenously given antibody, which helps to neutralize the toxins produced by C. Diff that damage the intestines, in combination with regular antibiotics used to treat C-diff. The sponsor is Merck.

This study is looking for patients with C. Diff-associated diarrhea. The study medication is made from healthy human stool, a product from living cells. It is administered by an enema, designed to reverse a disease process. Also thought to restore the normal balance of microorganisms in the intestines. The sponsor is Rebiotix.

Please contact Suzy Hernandez, CCRC for more information at:
suzy.hernandez@capitaldigestivecare.com / (301) 652-5520

Celiac

​This trial is for patients who have been diagnosed with Celiac Disease. They must be Gluten-Free for 11 months or longer. The patient must be showing active to moderate severe symptoms within the past month. The sponsor is Actelion.

Please contact Suzy Hernandez, CCRC for more information at:
suzy.hernandez@capitaldigestivecare.com / (301) 652-5520

Colorectal Cancer Screening

This study is for patients who are 65 yrs. or older and haven’t had a colonoscopy for at least 9 years. The study is an experimental diagnostic test that is designed to detect colorectal cancer and pre-cancer in the stool. The study requires a single stool sample to be collected by the patient using a stool collection kit given by the study staff. The sponsor is Exact Science Corporation.

Please contact Suzy Hernandez, CCRC for more information at:
suzy.hernandez@capitaldigestivecare.com / (301) 652-5520

Constipation

For patients 18-80, this is a 12 week study using the medication plecanatide which causes an increase in the amount of fluid in the intestines. This study is for patients with a history of less than 3 bowel movements per week. This study is for subjects who have NOT been diagnosed with Irritable Bowel Syndrome. The sponsor is Synergy.

Please contact Suzy Hernandez, CCRC for more information at:
suzy.hernandez@capitaldigestivecare.com / (301) 652-5520

Eosinophilic Esophagitis (EoE)

The study is for patients for are 18 to 65 years old, who have been diagnosed with Eosinophilic Esophagitis (EoE) and are currently showing symptoms of dysphagia. The sponsor for this trial is Receptos.

Please contact Suzy Hernandez, CCRC for more information at:
suzy.hernandez@capitaldigestivecare.com / (301) 652-5520

H. Pylori

​The trial is for subjects who have tested positive for Helicobacter pylori, also known as H. Pylori. The patient can have been diagnosed in the past, but cannot have been treated for this occurrence. The patient cannot have taken any acid reflux or GERD medications within two weeks of signing the informed consent. This is an oral combinational drug of three FDA approved medications. The sponsor for this trial is RedHill Biopharma.

Please contact Suzy Hernandez, CCRC for more information at:
suzy.hernandez@capitaldigestivecare.com / (301) 652-5520

Inflammatory Bowel Disease

Crohn's Disease

We have multiple studies for Crohn’s disease. The potential patient needs to have moderate to severe symptoms / disease activity. The patient needs to have failed tradition therapy (6-Mp, Steroids, TNF-Inhibitors, etc.). The patient must be willing to undergo a colonoscopy. Clinical trial medications include oral agents, oral antibiotics, sub-cutaneous medication, IV infusions, and more. There are several sponsors for this indication.

Please contact Suzy Hernandez, CCRC for more information at:
suzy.hernandez@capitaldigestivecare.com / (301) 652-5520

 

Ulcerative Colitis

We have multiple studies for ulcerative colitis (UC). The potential patient needs to have moderate to severe symptoms / disease activity. Clinical trial medications include oral agents, herbal agents, sub-cutaneous medication, IV infusions, and more. There are several sponsors for this indication.

Please contact Suzy Hernandez, CCRC for more information at:
suzy.hernandez@capitaldigestivecare.com / (301) 652-5520

Liver Cirrhosis

This trial is for patients who have been diagnosed with liver cirrhosis, who are currently showing retention of abdominal fluid. The patient cannot have history of alcohol or substance abuse within 3 months of signing the informed consent to participate. The subject cannot be taking antibiotics, and cannot be diabetic. The sponsor for this trial is Salix.

Please contact Suzy Hernandez, CCRC for more information at:
suzy.hernandez@capitaldigestivecare.com / (301) 652-5520

Ulcerative Colitis

This trial is for patients who are age 18 and older who are suffering from moderate to severe ulcerative colitis. They must not have been previously treated with Vedolizumab (Entyvio) or Natalizumab (Antegres).

Please contact Suzy Hernandez, CCRC for more information at:
suzy.hernandez@capitaldigestivecare.com / (301) 652-5520

Our Ijamsville & Takoma Park Offices have updated information

Please view the Ijamsville & Takoma Park location pages to see updated information.

View Locations